Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBIT Margin (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of EBIT Margin data on record, last reported at 25.58% in Q4 2025.

  • For Q4 2025, EBIT Margin fell 7146.0% year-over-year to 25.58%; the TTM value through Dec 2025 reached 5.52%, up 1081.0%, while the annual FY2025 figure was 5.52%, 1081.0% up from the prior year.
  • EBIT Margin reached 25.58% in Q4 2025 per APLS's latest filing, down from 48.67% in the prior quarter.
  • Across five years, EBIT Margin topped out at 481.36% in Q4 2021 and bottomed at 31185.71% in Q2 2021.
  • Average EBIT Margin over 5 years is 1945.69%, with a median of 57.74% recorded in 2023.
  • The widest YoY moves for EBIT Margin: up 3027514bps in 2022, down -120524bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 481.36% in 2021, then tumbled by -250bps to 723.88% in 2022, then surged by 92bps to 57.74% in 2023, then soared by 179bps to 45.88% in 2024, then crashed by -156bps to 25.58% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 25.58% in Q4 2025, 48.67% in Q3 2025, and 18.65% in Q2 2025.